Perspectum, a provider of precision medical imaging technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer, announced the completion of its first close of $36 million Series C funding round.
Oppenheimer Holdings led the investment round bringing the company’s total funding to date to more than $120 million.
Commenting on the funding news, Rajarshi Banerjee, CEO of Perspectum, said: “This new funding will help us to continue innovating new products that will make healthcare safer by providing non-invasive alternatives to biopsy, totally changing how and when we can see and treat many diseases.”
Since launching the precision medical imaging software platform in 2011, the company claims to have helped care providers assess and monitor nearly 77 million adults living with chronic liver disease U.S. The software aids in the early detection, diagnosis, and targeted treatment of large-scale, complex health problems, according to the company.
Medical imaging technology companies have attracted almost $4 billion in funding to date. The latest funding rounds in medical imaging include:
Prenuvo, a medical technology company specializing in whole-body medical diagnostic imaging for early detection of cancer and other diseases, raised $70 million in Series A funding led by Felicis, with participation from existing investors.
Elephas, a provider of cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development, raised $41.5 million in Series B funding led by ARCH Venture Partners with participation from Moore Strategic Ventures and Tao Capital Partners, Northpond Ventures, Sands Capital, and WARF Ventures.
FathomX, a provider of AI-powered medical imaging solutions to diagnose breast cancer in its early stage, raised $1.6 million in a Seed funding round.
Aidoc, a provider of AI-based decision support software that analyzes medical imaging to provide comprehensive solutions for flagging acute abnormalities across the body, helping radiologists prioritize life-threatening cases and expedite patient care, raised $110 million in Series D funding led by TCV and Alpha Intelligence Capital (AIC), with participation from CDIB Capital.